Companies Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Ligand Pharmaceuticals’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers78th pct.Of 21 peer CEOs
CEO pay, last three years
- $6,216,518FY2023
- $12,914,980FY2024
- $11,472,095FY2025
CEO total pay was $11,472,095 in fiscal 2025, down from $12,914,980 in fiscal 2024.
FY2025: salary $724,500 · bonus $0 · stock awards $5,520,493 · option awards $4,441,120
Executives and directors
Andrew Reardon · General CounselOctavio Espinoza · CFOTodd Davis · CEOJason Haas · Independent DirectorJason M. Aryeh · Independent DirectorJohn L. LaMattina · Independent DirectorJohn W. Kozarich · Independent DirectorMartine Zimmermann · Independent DirectorNancy R. Gray · Independent DirectorStephen L. Sabba · Independent Director
Frequently asked questions
Who was the highest-paid executive at Ligand Pharmaceuticals in fiscal 2025?
As disclosed, Todd Davis (Chief Executive Officer) was the highest-paid executive at Ligand Pharmaceuticals in fiscal 2025, with total compensation of $11,472,095.
How does Ligand Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Todd Davis's total compensation ranked at the 78th percentile of Ligand Pharmaceuticals's disclosed peer group.
What is Ligand Pharmaceuticals's CEO-to-median employee pay ratio?
As disclosed, Ligand Pharmaceuticals's CEO-to-median employee pay ratio was 28:1.
How did shareholders vote on Ligand Pharmaceuticals's executive compensation?
As disclosed, 94.17% of shareholders supported Ligand Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Ligand Pharmaceuticals spend in total on board compensation for fiscal 2025?
As disclosed, Ligand Pharmaceuticals reported total board compensation of $1,327,383 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Davis | $724,500 | $0 | $5,520,493 | $4,441,120 | $764,400 | $0 | $21,582 | $11,472,095 |
| Chief Executive Officer | ||||||||
| Tavo Espinoza | 522,825 | 0 | 1,932,219 | 1,554,411 | 357,750 | 0 | 14,943 | 4,382,148 |
| Chief Financial Officer | ||||||||
| Andrew Reardon | 476,675 | 0 | 1,656,171 | 1,332,345 | 268,800 | 0 | 13,291 | 3,747,282 |
| Chief Legal Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Davis | $11,472,095 | $12,914,980 | $6,216,518 | ↓ −1,442,885 |
| Tavo Espinoza | 4,382,148 | 3,298,556 | 2,450,631 | ↑ +1,083,592 |
| Andrew Reardon | 3,747,282 | 3,270,956 | 2,337,081 | ↑ +476,326 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Tavo Espinoza | PSU | 2025-03-04 | — | 9,280 | — | 18,560 | $1,069,613 |
| Andrew Reardon | RSU | 2025-03-04 | — | — | 6,415 | — | 739,393 |
| Andrew Reardon | PSU | 2025-03-04 | — | 7,954 | — | 15,908 | 916,778 |
| Todd Davis | RSU | 2025-03-04 | — | — | 21,382 | — | 2,464,489 |
| Tavo Espinoza | RSU | 2025-03-04 | — | — | 7,484 | — | 862,606 |
| Todd Davis | OPTION | 2025-03-04 | — | — | 93,476 | — | 4,441,120 |
| Tavo Espinoza | OPTION | 2025-03-04 | — | — | 32,717 | — | 1,554,411 |
| Andrew Reardon | OPTION | 2025-03-04 | — | — | 28,043 | — | 1,332,345 |
| Todd Davis | PSU | 2025-03-04 | — | 26,514 | — | 53,028 | 3,056,004 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Tavo Espinoza | $862,606 | $1,069,613 | $1,554,411 | 30.7% |
| Andrew Reardon | 739,393 | 916,778 | 1,332,345 | 30.7% |
| Todd Davis | 2,464,489 | 3,056,004 | 4,441,120 | 30.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Todd Davis | Option | 520 | 67.03 | — |
| Tavo Espinoza | Option | 972 | 52.84 | — |
| Tavo Espinoza | Option | 1,655 | 67.03 | — |
| Andrew Reardon | PSU | 3,464 | — | 654,938 |
| Tavo Espinoza | PSU | 3,695 | — | 698,614 |
| Andrew Reardon | Option | 4,489 | 75.09 | — |
| Tavo Espinoza | Option | 4,789 | 75.09 | — |
| Tavo Espinoza | Option | 5,000 | 63.62 | — |
| Andrew Reardon | PSU | 7,954 | — | 1,503,863 |
| Tavo Espinoza | PSU | 8,810 | — | 1,665,707 |
| Andrew Reardon | PSU | 8,810 | — | 1,665,707 |
| Tavo Espinoza | PSU | 9,280 | — | 1,754,570 |
| Todd Davis | PSU | 10,391 | — | 1,964,626 |
| Andrew Reardon | Option | 12,151 | 52.27 | — |
| Andrew Reardon | RSU | 13,109 | — | 2,478,519 |
| Todd Davis | Option | 13,468 | 75.09 | — |
| Tavo Espinoza | RSU | 14,304 | — | 2,704,457 |
| Tavo Espinoza | Option | 15,856 | 89.2 | — |
| Andrew Reardon | Option | 15,856 | 89.2 | — |
| Andrew Reardon | Option | 22,784 | 115.26 | — |
| Todd Davis | PSU | 26,514 | — | 5,013,002 |
| Tavo Espinoza | Option | 26,582 | 115.26 | — |
| Todd Davis | Option | 33,000 | 69.7 | — |
| Todd Davis | PSU | 39,644 | — | 7,495,491 |
| Todd Davis | RSU | 48,674 | — | 9,202,793 |
| Todd Davis | Option | 71,350 | 89.2 | — |
| Todd Davis | Option | 75,949 | 115.26 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John W. KozarichIndependent · Nominating/Governance · Science & Technology Operations | $82,039 | $128,142 | $262,888 | — | $0 | $473,069 |
| Jason HaasIndependent · Audit · Human Capital (Chair) · Strategic Transaction · Human Capital Management and Compensation (Chair) | 67,039 | 128,142 | 262,888 | — | 0 | 458,069 |
| Stephen L. SabbaIndependent · Audit (Chair) · Strategic Transaction | 62,039 | 128,142 | 262,888 | — | 0 | 453,069 |
| Jason M. AryehIndependent · Nominating/Governance (Chair) · Human Capital · Strategic Transaction · Human Capital Management and Compensation | 59,539 | 128,142 | 262,888 | — | 0 | 450,569 |
| Nancy R. GrayIndependent · Audit · Nominating/Governance · Science & Technology Operations | 57,039 | 128,142 | 262,888 | — | 0 | 448,069 |
| Martine ZimmermannIndependent · Audit | 53,155 | 128,142 | 262,888 | — | 0 | 444,185 |
| John L. LaMattinaIndependent · Human Capital · Science & Technology Operations · Human Capital Management and Compensation | 49,539 | 128,142 | 262,888 | — | 0 | 440,569 |
| Todd C. DavisEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $42,000 |
|---|---|
| Annual equity retainer | $375,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 5x annual retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $430,389 |
| Equity awards (grant-date value) | $896,994 |
| All other compensation | $0 |
| Total cost of the board | $1,327,383 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Ligand Pharmaceuticals as a peer
Companies that benchmark against LGND
8 companies name LGND as a compensation peer
The list of companies that name LGND as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
GI PartnersAKRO Akero TherapeuticsSIGA SIGA TechnologiesARDX ArdelyxHALO Halozyme TherapeuticsSLNO Soleno TherapeuticsIDYA IDEAYA BiosciencesGPCR Structure TherapeuticsVERA Vera TherapeuticsCGON CG OncologyMLTX MoonLake ImmunotherapeuticsSPRY ARS Pharmaceuticals Cassava SciencesCPRX Catalyst Pharmaceuticals AtlasETNB 89bioPTGX Protagonist TherapeuticsDAWN Day One BiopharmaceuticalsGERN GeronINVA InnovivaLQDA Liquidia
Peer reciprocity
The companies Ligand Pharmaceuticals names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Soleno Therapeutics | 2024 | Anish Bhatnagar | $640,000 | $46,883,000 | $3,231,230 | $403,200 | $51,160,430 |
| 2 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | Protagonist Therapeutics | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 4 | CG Oncology | 2025 | Arthur Kuan | 690,000 | 3,451,884 | 7,350,515 | 414,000 | 11,928,401 |
| 5 | Ligand Pharmaceuticals | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 6 | Akero Therapeutics | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 7 | Geron | 2025 | Harout Semerjian | 321,538 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 8 | ARS Pharmaceuticals | 2025 | Richard Lowenthal | 700,000 | — | 6,176,110 | 315,000 | 9,656,400 |
| 9 | Ideaya Biosciences | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 10 | Structure Therapeutics | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 11 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 12 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 13 | Liquidia | 2025 | Roger Jeffs | 824,000 | 5,590,992 | 0 | 1,254,400 | 7,712,736 |
| 14 | 89bio | 2024 | Rohan Palekar | 646,000 | 1,996,000 | 4,623,592 | 337,535 | 7,619,426 |
| 15 | Vera Therapeutics | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 16 | Day One Biopharmaceuticals | 2024 | Jeremy Bender | 680,000 | 2,700,280 | 2,664,697 | 501,800 | 6,560,577 |
| 17 | Innoviva | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 18 | MoonLake Immunotherapeutics | 2025 | Jorge Santos da Silva | 762,386 | 4,000,021 | 0 | 0 | 4,943,209 |
| 19 | Siga Technologies | 2025 | Diem Nguyen | 927,000 | 1,853,992 | 0 | 0 | 3,244,492 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Ligand Pharmaceuticals | 150% | not disclosed | No | Aon |
| 89bio | 95% | not disclosed | No | Aon |
| Akero Therapeutics | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| ARS Pharmaceuticals | not disclosed | Option 100 | not disclosed | Aon |
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| CG Oncology | 100% | Options 72 · PSU 28 | No | Pay Governance |
| Day One Biopharmaceuticals | 123%% | Stock Options 50 · RSUs 50 | not disclosed | Compensia Inc. |
| Geron | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Ideaya Biosciences | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Innoviva | 105% | not disclosed | not disclosed | Meridian |
| Liquidia | not disclosed | RSU 50 · PSU 50 | not disclosed | FW Cook |
| MoonLake Immunotherapeutics | not disclosed | not disclosed | not disclosed | Deloitte |
| Protagonist Therapeutics | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Siga Technologies | not disclosed | RSU 50 · PSU 50 | not disclosed | Pay Governance LLC |
| Soleno Therapeutics | not disclosed | not disclosed | not disclosed | Aon plc |
| Structure Therapeutics | 125% | Options 67 · RSU 33 | No | Aon |
| Vera Therapeutics | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-05 | 16,497,712 | 1,021,948 | 14,099 | 94.17% | Passed |
| 2025 | 2025-06-06 | 15,576,200 | 1,183,843 | 59,973 | 92.94% | Passed |
| 2024 | 2024-06-14 | 14,264,205 | 1,253,085 | 8,346 | 91.92% | Passed |
| 2023 | 2023-06-09 | 12,379,762 | 1,698,528 | 21,290 | 87.94% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-05 | 94.17%a |
| 2025 | 2025-06-06 | 92.94%b |
| 2024 | 2024-06-14 | 91.92%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 28 : 1 |
|---|---|
| CEO total compensation | $11,472,095 |
| Median employee compensation | $403,453 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 1,420 | $233 | $330,749 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 780 | 232 | 180,991 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 370 | 231 | 85,422 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 98 | 230 | 22,511 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 600 | 227 | 136,470 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 116 | 234 | 27,154 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 105 | 233 | 24,420 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 932 | 229 | 213,198 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 80 | 227 | 18,189 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 800 | 234 | 187,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 165 | 232 | 38,258 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 1 | 230 | 230 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-12 | — | 459 | — | — | 1 insider, 1 accrual row | ||
| John W. Kozarich | Director | 2026-05-12 | D | 459 | 224 | 102,816 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-12 | A | 459 | 70 | 31,905 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-13 | A | 1,575 | 70 | 109,478 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-13 | — | 1,575 | — | — | 1 insider, 1 accrual row | ||
| John W. Kozarich | Director | 2026-05-13 | D | 1,575 | 224 | 352,013 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | A | 764 | 64 | 48,606 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-27 | — | 1,736 | — | — | 1 insider, 2 accrual rows | ||
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | A | 972 | 53 | 51,360 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 584 | 229 | 133,487 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 400 | 227 | 90,712 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 200 | 230 | 46,082 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 1,216 | 229 | 279,033 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 1,432 | 226 | 323,585 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 491 | 224 | 109,958 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 677 | 225 | 152,459 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy R. Gray | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | D | 182 | 237 | 43,134 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy R. Gray | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 232 | 248 | 57,562 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 3,405 | 252 | 856,752 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 257 | 247 | 63,536 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 697 | 250 | 173,924 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-10 | D | 500 | 250 | 125,000 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-11 | D | 4,500 | 250 | 1,125,000 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-12 | — | 1,000 | — | — | 1 insider, 1 accrual row | ||
| Jason Haas | Director | 2026-06-12 | D | 3,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | A | 1,000 | 52 | 51,560 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 3,461 | 256 | 886,286 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 3,000 | 255 | 765,034 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | A | 3,000 | 52 | 154,680 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | D | 2,145 | 254 | 544,830 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | D | 2,145 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | A | 2,145 | 66 | 141,849 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-06-30 | A | 17 | 161 | 2,732 | Common | Form 4 ↗ |
| Todd C. Davis | Director | 2026-06-30 | A | 132 | 161 | 21,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-30 | A | 132 | 161 | 21,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 1,119 | 312 | 348,815 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 396 | 309 | 122,359 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 100 | 315 | 31,458 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 1,081 | 312 | 337,573 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 104 | 310 | 32,261 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 900 | 316 | 284,200 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 600 | 317 | 190,291 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 700 | 313 | 219,420 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 991 | 292 | 289,086 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 503 | 290 | 145,771 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 356 | 289 | 102,795 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 1,032 | 287 | 295,974 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 33 | 285 | 9,390 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 105 | 284 | 29,834 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 409 | 293 | 119,763 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 157 | 286 | 44,861 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 1,214 | 288 | 349,357 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 200 | 291 | 58,120 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | A | 6,138 | 52 | 316,475 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 2,074 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 3,348 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 16,179 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 2,869 | 56 | 159,947 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 16,179 | 53 | 854,898 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 7,171 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 3,348 | 69 | 230,142 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | D | 6,138 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | D | 7,138 | 293 | 2,090,062 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 31,641 | 292 | 9,241,229 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 7,171 | 57 | 410,325 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 2,074 | 70 | 145,263 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 2,869 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 300 | 284 | 85,196 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 2,115 | 286 | 605,649 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 400 | 289 | 115,592 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 1,800 | 285 | 513,301 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 385 | 288 | 110,697 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-09-10 | D | 1,200 | 285 | 342,000 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-09-22 | D | 115 | 299 | 34,328 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-02 | — | 340 | — | — | 1 insider, 1 accrual row | ||
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 17 | 308 | 5,232 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 235 | 307 | 72,190 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 404 | 306 | 123,698 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 1,535 | 305 | 467,431 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 1,976 | 304 | 599,804 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 833 | 303 | 251,991 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | A | 340 | 52 | 17,772 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 320 | 16,025 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 1,209 | 320 | 387,384 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 52 | 320 | 16,652 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 318 | 15,912 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 318 | 15,887 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 120 | 323 | 38,777 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 200 | 321 | 64,288 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 320 | 320 | 102,390 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 440 | 319 | 140,240 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 280 | 318 | 89,014 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 80 | 315 | 25,166 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 403 | 314 | 126,441 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 634 | 313 | 198,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 520 | 312 | 162,093 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 490 | 311 | 152,201 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 522 | 310 | 161,773 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 708 | 308 | 218,369 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 283 | 307 | 86,992 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-11-02 | D | 700 | 320 | 224,298 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 138 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 1,420 | $233 | $330,749 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 780 | 232 | 180,991 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 370 | 231 | 85,422 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 98 | 230 | 22,511 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 600 | 227 | 136,470 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 116 | 234 | 27,154 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 105 | 233 | 24,420 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 932 | 229 | 213,198 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 80 | 227 | 18,189 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | D | 800 | 234 | 187,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-05-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 165 | 232 | 38,258 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-01 | D | 1 | 230 | 230 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-12 | D | 459 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-12 | D | 459 | 224 | 102,816 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-12 | A | 459 | 70 | 31,905 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-13 | A | 1,575 | 70 | 109,478 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-13 | D | 1,575 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-05-13 | D | 1,575 | 224 | 352,013 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | A | 764 | 64 | 48,606 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | D | 764 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | A | 972 | 53 | 51,360 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-05-27 | D | 972 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 584 | 229 | 133,487 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 400 | 227 | 90,712 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 200 | 230 | 46,082 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 1,216 | 229 | 279,033 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 1,432 | 226 | 323,585 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 491 | 224 | 109,958 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-01 | D | 677 | 225 | 152,459 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Kozarich | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy R. Gray | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-06-05 | D | 182 | 237 | 43,134 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-05 | A | 2,938 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nancy R. Gray | Director | 2026-06-05 | A | 836 | 0 | 0 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 232 | 248 | 57,562 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 3,405 | 252 | 856,752 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 257 | 247 | 63,536 | Common | Form 4 ↗ |
| John L. LaMattina | Director | 2026-06-10 | D | 697 | 250 | 173,924 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-10 | D | 500 | 250 | 125,000 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-06-11 | D | 4,500 | 250 | 1,125,000 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 1,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 3,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | A | 1,000 | 52 | 51,560 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 3,461 | 256 | 886,286 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | D | 3,000 | 255 | 765,034 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-06-12 | A | 3,000 | 52 | 154,680 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | D | 2,145 | 254 | 544,830 | Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | D | 2,145 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen L. Sabba | Director | 2026-06-16 | A | 2,145 | 66 | 141,849 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-06-30 | A | 17 | 161 | 2,732 | Common | Form 4 ↗ |
| Todd C. Davis | Director | 2026-06-30 | A | 132 | 161 | 21,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-06-30 | A | 132 | 161 | 21,214 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 1,119 | 312 | 348,815 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 396 | 309 | 122,359 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 100 | 315 | 31,458 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 1,081 | 312 | 337,573 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 104 | 310 | 32,261 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 900 | 316 | 284,200 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 600 | 317 | 190,291 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-07-01 | D | 700 | 313 | 219,420 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 991 | 292 | 289,086 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 503 | 290 | 145,771 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 356 | 289 | 102,795 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 1,032 | 287 | 295,974 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 33 | 285 | 9,390 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 105 | 284 | 29,834 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 409 | 293 | 119,763 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 157 | 286 | 44,861 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 1,214 | 288 | 349,357 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-08-03 | D | 200 | 291 | 58,120 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | A | 6,138 | 52 | 316,475 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 2,074 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 3,348 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 16,179 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 2,869 | 56 | 159,947 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 16,179 | 53 | 854,898 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 7,171 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 3,348 | 69 | 230,142 | Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | D | 6,138 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Haas | Director | 2026-08-12 | D | 7,138 | 293 | 2,090,062 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 31,641 | 292 | 9,241,229 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 7,171 | 57 | 410,325 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | A | 2,074 | 70 | 145,263 | Common | Form 4 ↗ |
| Tavo Espinoza | Chief Financial Officer | 2026-08-12 | D | 2,869 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 300 | 284 | 85,196 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 2,115 | 286 | 605,649 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 400 | 289 | 115,592 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 1,800 | 285 | 513,301 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-09-03 | D | 385 | 288 | 110,697 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-09-10 | D | 1,200 | 285 | 342,000 | Common | Form 4 ↗ |
| Martine Zimmermann | Director | 2026-09-22 | D | 115 | 299 | 34,328 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 340 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 17 | 308 | 5,232 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 235 | 307 | 72,190 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 404 | 306 | 123,698 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 1,535 | 305 | 467,431 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 1,976 | 304 | 599,804 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | D | 833 | 303 | 251,991 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-10-02 | A | 340 | 52 | 17,772 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 320 | 16,025 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 1,209 | 320 | 387,384 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 52 | 320 | 16,652 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 318 | 15,912 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-10-30 | D | 50 | 318 | 15,887 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 120 | 323 | 38,777 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 200 | 321 | 64,288 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 320 | 320 | 102,390 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 440 | 319 | 140,240 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 280 | 318 | 89,014 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 80 | 315 | 25,166 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 403 | 314 | 126,441 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 634 | 313 | 198,350 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 520 | 312 | 162,093 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 490 | 311 | 152,201 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 522 | 310 | 161,773 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 708 | 308 | 218,369 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | D | 283 | 307 | 86,992 | Common | Form 4 ↗ |
| Andrew Reardon | CLO & Secretary | 2026-11-02 | A | 5,000 | 52 | 261,350 | Common | Form 4 ↗ |
| Jason M. Aryeh | Director | 2026-11-02 | D | 700 | 320 | 224,298 | Common | Form 4 ↗ |
Sources (186 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Todd Davis. DEF 14A, filed 2026-04-21. Section “SUMMARY COMPENSATION TABLE” · page 63. As printed: 11,472,095. View filing ↗
- Section 01, Tavo Espinoza. DEF 14A, filed 2026-04-21. Section “SUMMARY COMPENSATION TABLE”. As printed: 4,382,148. View filing ↗
- Section 01, Andrew Reardon. DEF 14A, filed 2026-04-21. Section “SUMMARY COMPENSATION TABLE”. As printed: 3,747,282. View filing ↗
- Section 03, Tavo Espinoza PSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Reardon RSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Reardon PSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Davis RSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tavo Espinoza RSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Davis OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Tavo Espinoza OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Reardon OPTION. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Todd Davis PSU. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-21. Section “CEO Pay Ratio”. As printed: 28 : 1. View filing ↗
- Section 08, John W. Kozarich. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 473,069. View filing ↗
- Section 08, Jason Haas. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 458,069. View filing ↗
- Section 08, Stephen L. Sabba. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 453,069. View filing ↗
- Section 08, Jason M. Aryeh. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 450,569. View filing ↗
- Section 08, Nancy R. Gray. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 448,069. View filing ↗
- Section 08, Martine Zimmermann. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 444,185. View filing ↗
- Section 08, John L. LaMattina. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 440,569. View filing ↗
- Section 08, Todd C. Davis. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-01. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-01. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-01. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-01. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-01. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-05-13. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John W. Kozarich 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen L. Sabba 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martine Zimmermann 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martine Zimmermann 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-06-05. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy R. Gray 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martine Zimmermann 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-06-05. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen L. Sabba 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy R. Gray 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John L. LaMattina 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-06-10. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-06-11. Form 4, filed 2026-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-06-12. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen L. Sabba 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen L. Sabba 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen L. Sabba 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-06-30. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Todd C. Davis 2026-06-30. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-06-30. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-08-03. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Haas 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Tavo Espinoza 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-09-03. Form 4, filed 2026-09-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martine Zimmermann 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Martine Zimmermann 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-10-02. Form 4, filed 2026-10-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Reardon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason M. Aryeh 2026-11-02. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-09. Item 5.07 · say-on-pay result. As reported: 94.17% (votes for as printed: 16,497,712). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-09. Item 5.07 · say-on-pay result. As reported: 92.94% (votes for as printed: 15,576,200). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-17. Item 5.07 · say-on-pay result. As reported: 91.92% (votes for as printed: 14,264,205). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 430,389 + equity 896,994 + all other 0 = 1,327,383, summed across the director compensation table rows.
- Soleno Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-22. CEO total compensation as printed in Soleno Therapeutics's own proxy. As printed: 51,160,430. View filing ↗
- Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
- Protagonist Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics's own proxy. As printed: 12,871,506. View filing ↗
- CG Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in CG Oncology's own proxy. As printed: 11,928,401. View filing ↗
- Ligand Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Ligand Pharmaceuticals's own proxy. As printed: 11,472,095. View filing ↗
- Akero Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics's own proxy. As printed: 10,465,855. View filing ↗
- Geron, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron's own proxy. As printed: 10,221,755. View filing ↗
- ARS Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in ARS Pharmaceuticals's own proxy. As printed: 9,656,400. View filing ↗
- Ideaya Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences's own proxy. As printed: 9,512,640. View filing ↗
- Structure Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics's own proxy. As printed: 8,429,887. View filing ↗
- Ardelyx, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. View filing ↗
- Catalyst Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. View filing ↗
- Liquidia, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Liquidia's own proxy. As printed: 7,712,736. View filing ↗
- 89bio, Section 10b CEO total. DEF 14A, filed 2025-04-15. CEO total compensation as printed in 89bio's own proxy. As printed: 7,619,426. View filing ↗
- Vera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics's own proxy. As printed: 6,986,410. View filing ↗
- Day One Biopharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals's own proxy. As printed: 6,560,577. View filing ↗
- Innoviva, Section 10b CEO total. DEF 14A, filed 2026-03-24. CEO total compensation as printed in Innoviva's own proxy. As printed: 5,400,197. View filing ↗
- MoonLake Immunotherapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in MoonLake Immunotherapeutics's own proxy. As printed: 4,943,209. View filing ↗
- Siga Technologies, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Siga Technologies's own proxy. As printed: 3,244,492. View filing ↗
- Section 10a, SIGA Technologies reciprocity. DEF 14A. SIGA Technologies names Ligand Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Innoviva reciprocity. DEF 14A. Innoviva names Ligand Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗